Phase III confirmatory trial of adjuvant girentuximab in patients with clear cell renal cell carcinoma stratified using the CAIX biomarker

Trial Profile

Phase III confirmatory trial of adjuvant girentuximab in patients with clear cell renal cell carcinoma stratified using the CAIX biomarker

Planning
Phase of Trial: Phase III

Latest Information Update: 19 Oct 2017

At a glance

  • Drugs Girentuximab (Primary)
  • Indications Renal cancer
  • Focus Biomarker; Registrational; Therapeutic Use
  • Sponsors Heidelberg Pharma AG
  • Most Recent Events

    • 19 Oct 2017 According to a Heidelberg Pharma AG media release, WILEX AG changed its name to Heidelberg Pharma AG.
    • 13 Jun 2013 Study title is not official; assumed registrational.
    • 13 Jun 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top